HHS Senior Advisor O’Brien Emerges As Azar’s Lead On Drug Pricing In 2019
Executive Summary
O’Brien assumes role from his late colleague and friend Dan Best as HHS closes out administrative items in the blueprint.
You may also be interested in...
Beyond The "Blueprint": The Next Stage For US HHS Drug Price Policy
Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.
Carrots Or Sticks: Which Way Might Medicare's Protected Classes Reforms Go?
UnitedHealthcare program for commercial members offers some implications. MyScripRewards encourages less costly HIV treatments using financial rewards, underscoring insurers’ tendency to favor carrots over sticks when it comes to coverage policies for such drugs.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.